Prelude Therapeutics

Prelude Therapeutics stock traded at USD 4.37 on Nasdaq on September 23, 2026, while Q2 revenue reached USD 5.7 million. Q2 net loss was USD 13.9 million.

Prelude Therapeutics stock has risen strongly in recent weeks after FDA clearance of the IND for breast cancer candidate PRT13722, with shares closing at USD 4.87 on September 18, 2026. The company is also advancing other targeted oncology programs that u

Phase 1 study of PRT13722 in patients with HR+ breast cancer anticipated to begin enrolling patients in the fourth quarter of 2026.WILMINGTON, Del., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology

Ryan Holmes, Andrew Moore, Max Foroutan, Jake Karwoski, Alex Grego, Carly Bachner1 Neha Bhagawat, Corey Basch, Soham Maity, Chun Chen, Sarah B. Pawley, Vijay Devannah, Sina Rezazadeh, Ross Kuskovsky, Joseph Rager, Kenneth Ray, Kirsten Gallagher, Yue Zou,

Monisha Sivakumar, Sarah Pawley, Corey Basch, Jimin Park, Justin Kurian, Anthony Reichelderfer, Yue Zou, Kirsten Gallagher, Miles Cowart, Joy Cote, Alexander Grego, Jessica Burtell, Amy Crossan, Michael Hulse, Anjana Agarwal, Arpita Mondal, Chun Chen, Vij

Koichi Ito, PhD Senior Director, Biology and Pharmacology, Prelude Therapeutics Incorporated The post Beyond Conventional Payloads: Unlocking New Therapeutic Landscapes With Precision Degrader-Antibody Conjugates (DACs) appeared first on Prelude Therapeut

Andrew W. Buesking, Sr. Director, Chemistry on behalf of the pDAC team The post Discovery of precision degrader antibody conjugates (pDACs) employing novel SMARCA2/4 degrader payloads appeared first on Prelude Therapeutics.

Norman Fultang1, Ashley Schwab1, Sharayu Chandratre1, Jake Karwoski1, Grace Davis1, Ian Johnson1, Neha Bhagwat1, Yue Zou1, Arpita Mondal1, Max Foroutan1, Min Wang1, Andrew Buesking1, Chun Chen1, Corey Basch1, Ryan Holmes1, Sang Hyun Lee1, Diane Heiser1, A

Neha Bhagwat1, Duanya Liu2, Xiaowei Wu1, Alexander Grego1, Amy Crossan1, Andrew Moore1, Arpita Mondal1, Carly Bachner1, Dani Roth1, Diego Elrio, John Rose1, Joseph Rager1, Joy Cote1, Kirsten Gallagher1, Klare Bersch1, Miles Cowart1, Min Wang1, Natalie Kur

Prelude Therapeutics, a clinical-stage biotech, has attracted fresh attention after securing an option agreement with Incyte for its JAK2V617F inhibitor program. The deal brings notable non-dilutive capital as well as a strategic investment. See our lates